Health Topics — Women's Health
Stress, Cortisol, and CBG: What the Research Suggests for Women
Women experience stress differently than men — biologically, not just psychologically. What the research shows about sex differences in the stress response, and what the CBG human trial found in its predominantly female sample.
The stress response is not experienced identically across sexes. Women are diagnosed with anxiety disorders at roughly twice the rate of men. They show different cortisol reactivity patterns. They carry the physiological cost of chronic stress differently — in hormonal disruption, in immune function, in sleep quality, in the particular way that stress and reproductive biology intersect across the lifespan.
This is not a deficit. It is biology. And it is the reason that stress regulation research, when read carefully, looks different for women than general population findings might suggest.
How the Stress Response Differs in Women
The HPA axis — the hypothalamic-pituitary-adrenal axis — is the body's central stress regulation system. When a threat is perceived, the hypothalamus signals the pituitary, which signals the adrenal glands to release cortisol. Cortisol mobilizes energy, sharpens attention, and prepares the body for response. Under normal conditions, a negative feedback loop brings cortisol back to baseline once the threat has passed.
Research has established that this system is modulated differently by estrogen and progesterone — the primary female sex hormones. Estrogen appears to amplify HPA axis reactivity in some contexts, increasing cortisol response magnitude. Progesterone, conversely, has been associated with dampening effects on the stress response, with some research suggesting it interacts with GABA receptors in ways that reduce anxiety-adjacent arousal. The ratio and cycling of these hormones across the menstrual cycle, and their dramatic shift across perimenopause and menopause, means that a woman's stress response is not a stable biological constant — it changes with reproductive phase.
This creates a research complexity that general stress and anxiety studies do not always address. A trial that recruits healthy adults without controlling for menstrual cycle phase, hormonal contraceptive use, or menopausal status is measuring a heterogeneous biological reality and calling it a single population. That is not a flaw unique to cannabinoid research — it is a historically pervasive limitation of biomedical research generally. But it matters when reading any stress research and asking what it means specifically for women.
Reading stress research as a woman
Much of the existing human trial data on cannabinoids and stress was not designed with female-specific biology as a primary variable. Sample compositions vary. Hormonal status is rarely reported. This does not invalidate the findings — it contextualizes them. Where studies have examined sex as a variable, differences have sometimes emerged. Where they have not, generalization requires caution.
The Endocannabinoid System and Female Stress Biology
Tier 2 — Preclinical and Mechanistic Evidence
The endocannabinoid system interacts with the HPA axis directly. Endocannabinoid signaling — primarily through anandamide and 2-AG acting on CB1 receptors — modulates cortisol release, dampens excessive stress reactivity, and participates in the termination of the stress response after a threat has resolved. When endocannabinoid tone is reduced, cortisol responses tend to persist longer and stress recovery is slower.
What the preclinical research has also shown is that this system is sex-sensitive. Estrogen appears to upregulate components of the endocannabinoid system — increasing anandamide synthesis and CB1 receptor expression in some brain regions. This may partly explain sex differences in stress reactivity and in the subjective experience of anxiety. It also means that interventions targeting the endocannabinoid system may not produce identical effects in male and female subjects — a distinction that cannabinoid research has only recently begun to examine directly.
Progesterone and its metabolites add another layer. Allopregnanolone — a progesterone metabolite — acts as a positive allosteric modulator of GABA-A receptors, producing anxiolytic and sedative effects. Its levels fluctuate across the menstrual cycle and drop sharply in the luteal phase and at menopause. The relationship between progesterone signaling, GABA activity, and endocannabinoid tone represents a convergence of stress-relevant biology that female-specific stress research is beginning to map.
CBG's pharmacological relevance to this picture is specific. CBG inhibits GABA reuptake, increasing GABAergic tone — the same inhibitory system that progesterone metabolites modulate. CBG also acts as an alpha-2 adrenoceptor agonist, a receptor system involved in regulating norepinephrine and the acute arousal component of the stress response. These mechanisms are preclinical. They are not clinical evidence. But they represent a pharmacological profile that intersects meaningfully with the biology of female stress regulation.
What the Cuttler Trial Shows — and What It Leaves Open
Tier 1 — Human Trial Evidence
The Cuttler et al. (2024) randomized controlled trial is the only published human trial examining CBG's acute effects on stress and anxiety. Thirty-four healthy adults received a single 20mg oral dose of CBG or placebo in a double-blind crossover design. Statistically significant reductions in self-reported anxiety and stress were observed at 20, 45, and 60 minutes post-dose compared to placebo.
The trial population was healthy adults. Hormonal status, menstrual cycle phase, and sex-specific subgroup analysis are not reported in the published data in ways that would allow female-specific conclusions to be drawn directly from this study. The findings apply to healthy adults as a group. They are consistent with CBG having a stress-reducing signal in humans — they do not yet establish what that signal looks like specifically in women across different hormonal contexts.
This is an honest account of where the research stands. The trial is well-designed and its findings are meaningful. The female-specific question it cannot answer is not a criticism of the trial — it is a specification of what the next generation of research needs to examine.
What exists and what is underway
Human trial: Cuttler et al. (2024) — healthy adults, acute dose, statistically significant anxiety and stress reduction. This is Tier 1 evidence for CBG and acute stress response in healthy humans.
In development: A clinical trial examining CBG's effects in menopausal women is currently in development at Washington State University. No data from this trial has been published. It may not be cited as current evidence. When it publishes, this article will be updated and the menopausal stress domain will move to Tier 1.
Preclinical: ECS-endocrine interactions, sex differences in CB1 expression, GABA-progesterone convergence — these are Tier 2 mechanistic findings. They provide biological rationale. They are not clinical evidence.
Cortisol Specifically: The Open Question
Cortisol is the most commonly discussed marker of stress response magnitude. It is measurable, it has established reference ranges, and it has been studied extensively in relation to chronic stress, burnout, sleep disruption, and hormonal health in women. It is also the variable that the existing CBG human trial did not directly measure.
The Cuttler (2024) trial measured self-reported stress and anxiety — validated subjective scales. These are appropriate and meaningful measures of the stress experience. They do not tell us whether CBG affected cortisol levels, cortisol reactivity, or the negative feedback loop that terminates cortisol release after a stressor. Those are open questions.
The preclinical literature suggests CBG may interact with HPA axis activity in ways relevant to cortisol regulation. Animal models have shown effects on anxiety-related behavior consistent with stress system modulation. Whether these translate to measurable cortisol effects in humans — and specifically in women across different hormonal phases — is precisely what future research will need to examine.
For women who have followed this question closely, the cortisol specificity gap is the most important limit of the current evidence. It is worth knowing it is a gap rather than discovering it later in less reliable sources.
What This Means for Women Following the Research
The picture that emerges from reading this literature carefully is more specific than general cannabinoid stress research suggests — and more honest about what remains uninvestigated.
The endocannabinoid system is meaningfully involved in female stress biology. The mechanisms by which CBG interacts with that system — GABA reuptake inhibition, alpha-2 adrenoceptor agonism — are pharmacologically relevant to the hormonal and neurological dimensions of stress that affect women specifically. One well-designed human trial has established an acute stress and anxiety signal in healthy adults. The cortisol question, the cycle-phase question, and the menopausal transition question are all open.
That is an honest starting point. It is not a complete answer. The research is underway, and this archive will reflect it accurately as it develops.
Stress regulation in women involves an intersection of the HPA axis, reproductive hormones, GABAergic signaling, and endocannabinoid tone that general stress research does not always address with the specificity it warrants. CBG's pharmacological profile intersects with several of these systems in ways that preclinical research has documented and one human trial has begun to confirm.
The Cuttler (2024) trial provides Tier 1 human evidence for CBG's acute effects on stress and anxiety in healthy adults. The female-specific questions — cortisol, cycle phase, menopausal transition — remain open and represent the most important next chapter in this research area. A clinical trial in menopausal women is in development. This archive will update when that data exists.
References
- Cuttler, C., Stuber, L., St. Pierre, M., & Theiss, S. (2024). Acute effects of cannabigerol on anxiety, stress, and mood: a double-blind, placebo-controlled, crossover study. Scientific Reports, 14. https://doi.org/10.1038/s41598-024-57363-2
- Cascio, M.G., Gauson, L.A., Stevenson, L.A., Ross, R.A., & Pertwee, R.G. (2010). Evidence that the plant cannabinoid cannabigerol is a highly potent alpha-2 adrenoceptor agonist and moderately potent 5-HT1A receptor antagonist. British Journal of Pharmacology, 159(1), 129–141.
- Hill, M.N., & Tasker, J.G. (2012). Endocannabinoid signaling, glucocorticoid-mediated negative feedback, and regulation of the hypothalamic-pituitary-adrenal axis. Neuroscience, 204, 5–16.
- Morena, M., Patel, S., Bains, J.S., & Hill, M.N. (2016). Neurobiological interactions between stress and the endocannabinoid system. Neuropsychopharmacology, 41(1), 80–102.
- Rubino, T., Zamberletti, E., & Parolaro, D. (2015). Endocannabinoids and mental disorders. Handbook of Experimental Pharmacology, 231, 261–283.
- Toufexis, D., Rivarola, M.A., Lara, H., & Viau, V. (2014). Stress and the reproductive axis. Journal of Neuroendocrinology, 26(9), 573–586.
- Zuardi, A.W. (2008). Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action. Revista Brasileira de Psiquiatria, 30(3), 271–280.
These statements have not been evaluated by the Food and Drug Administration. J.P. Hemp Company products are not intended to diagnose, treat, cure, or prevent any disease.